NASDAQ:PACB - Pacific Biosciences of California Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $3.75 +0.01 (+0.27 %) (As of 07/20/2018 04:00 PM ET)Previous Close$3.75Today's Range$3.70 - $3.8252-Week Range$2.02 - $5.70Volume537,071 shsAverage Volume770,126 shsMarket Capitalization$493.22 millionP/E Ratio-4.31Dividend YieldN/ABeta1.51 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company's single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes single molecule biochemical reactions in real time. The company also provides consumable products, including SMRT cells, as well as various reagent kits, such as template preparation, binding, and sequencing kits. Its customers include research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. The company markets its products through a direct sales force in North America and Europe, as well as primarily through distribution partners in Asia, the Middle East, and Latin America. The company was formerly known as Nanofluidics, Inc. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California. Receive PACB News and Ratings via Email Sign-up to receive the latest news and ratings for PACB and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Analytical instruments Sub-IndustryLife Sciences Tools & Services SectorMedical SymbolNASDAQ:PACB CUSIP69404D10 Webwww.pacb.com Phone650-521-8000 Debt Debt-to-Equity Ratio0.14 Current Ratio4.64 Quick Ratio3.60 Price-To-Earnings Trailing P/E Ratio-4.31 Forward P/E Ratio-5.86 P/E GrowthN/A Sales & Book Value Annual Sales$93.47 million Price / Sales5.29 Cash FlowN/A Price / CashN/A Book Value$0.74 per share Price / Book5.07 Profitability EPS (Most Recent Fiscal Year)($0.87) Net Income$-92,180,000.00 Net Margins-105.22% Return on Equity-91.11% Return on Assets-58.10% Miscellaneous Employees456 Outstanding Shares131,880,000Market Cap$493.22 Pacific Biosciences of California (NASDAQ:PACB) Frequently Asked Questions What is Pacific Biosciences of California's stock symbol? Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB." How were Pacific Biosciences of California's earnings last quarter? Pacific Biosciences of California (NASDAQ:PACB) posted its quarterly earnings results on Wednesday, May, 2nd. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by $0.01. The biotechnology company had revenue of $19.40 million for the quarter, compared to the consensus estimate of $23.97 million. Pacific Biosciences of California had a negative return on equity of 91.11% and a negative net margin of 105.22%. Pacific Biosciences of California's quarterly revenue was down 22.1% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.26) earnings per share. View Pacific Biosciences of California's Earnings History. When is Pacific Biosciences of California's next earnings date? Pacific Biosciences of California is scheduled to release their next quarterly earnings announcement on Tuesday, July, 31st 2018. View Earnings Estimates for Pacific Biosciences of California. What price target have analysts set for PACB? 2 brokers have issued 12 month price objectives for Pacific Biosciences of California's stock. Their predictions range from $4.00 to $6.80. On average, they anticipate Pacific Biosciences of California's share price to reach $5.40 in the next twelve months. This suggests a possible upside of 44.0% from the stock's current price. View Analyst Ratings for Pacific Biosciences of California. What is the consensus analysts' recommendation for Pacific Biosciences of California? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." Who are some of Pacific Biosciences of California's key competitors? Some companies that are related to Pacific Biosciences of California include Accelerate Diagnostics (AXDX), Quanterix (QTRX), Fluidigm (FLDM), Harvard Bioscience (HBIO), Eyepoint Pharmaceuticals (EYPT), HTG Molecular Diagnostics (HTGM), Arrayit Corp common stock (ARYC), Aethlon Medical (AEMD), Precipio (PRPO), Pressure Biosciences (PBIO), Scientific Industries (SCND) and PositiveID (PSID). Who are Pacific Biosciences of California's key executives? Pacific Biosciences of California's management team includes the folowing people: Dr. Michael W. Hunkapiller, Exec. Chairman, CEO & Pres (Age 69)Ms. Susan K. Barnes, Sr. VP & CFO (Age 64)Mr. James Michael Phillips, Sr. VP of R&D (Age 67)Mr. Kevin P. Corcoran, Sr. VP of Market Devel. (Age 59)Ms. Kathy P. Ordoñez, Chief Commercial Officer, Exec. VP & Director (Age 67) Has Pacific Biosciences of California been receiving favorable news coverage? Media headlines about PACB stock have trended somewhat positive on Saturday, Accern Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Pacific Biosciences of California earned a news impact score of 0.08 on Accern's scale. They also assigned press coverage about the biotechnology company an impact score of 44.95 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term. How do I buy shares of Pacific Biosciences of California? Shares of PACB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Pacific Biosciences of California's stock price today? One share of PACB stock can currently be purchased for approximately $3.75. How big of a company is Pacific Biosciences of California? Pacific Biosciences of California has a market capitalization of $493.22 million and generates $93.47 million in revenue each year. The biotechnology company earns $-92,180,000.00 in net income (profit) each year or ($0.87) on an earnings per share basis. Pacific Biosciences of California employs 456 workers across the globe. How can I contact Pacific Biosciences of California? Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-521-8000 or via email at [email protected] MarketBeat Community Rating for Pacific Biosciences of California (NASDAQ PACB)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 202 (Vote Outperform)Underperform Votes: 219 (Vote Underperform)Total Votes: 421MarketBeat's community ratings are surveys of what our community members think about Pacific Biosciences of California and other stocks. Vote "Outperform" if you believe PACB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PACB will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/21/2018 by MarketBeat.com StaffFeatured Article: What kind of dividend yield to CEF's pay?